Kardigan (KARD) Stock Analysis
NASDAQHealthcareBiotechnology
What Kardigan does
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Key metrics
ETFs linked to KARD
Broad-market and Healthcare sector ETFs an investor holding Kardigan is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how KARD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze KARD in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Kardigan?
- Kardigan trades under the ticker KARD on NASDAQ.
- Which exchange is KARD listed on?
- KARD is listed on NASDAQ.
- What sector does Kardigan operate in?
- Kardigan is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze KARD in a portfolio?
- PortView shows KARD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.